Thymidine kinase in breast cancer
- PMID: 2223587
- PMCID: PMC1971480
- DOI: 10.1038/bjc.1990.352
Thymidine kinase in breast cancer
Abstract
The enzyme thymidine kinase is associated with DNA synthesis. Thymidine kinase serum levels were studied in normal controls (n = 20), patients with primary breast cancer (n = 60), patients with systemic breast cancer (n = 20) and as a non-cancer disease control group in patients with inflammatory gastrointestinal disorders (n = 20). Comparison of pretreatment values in the cancer patients with the normal controls showed a significant difference between the three groups in relation to stage of disease: mean values 4.22 (+/- 1.08), 6.22 (+/- 2.24) and 9.79 (+/- 7.56) pmol ml-1 h-1 for normal controls, operable breast cancer and systemic breast cancer respectively (P less than 0.005; analysis of variance). Patients with systemic breast cancer had a significantly elevated serum thymidine kinase level compared to controls (P less than 0.01) and patients with primary operable cancer (P less than 0.05). Patients with primary operable cancer had significantly higher serum thymidine kinase levels over normal controls (P less than 0.01). Mean serum TK in patients with inflammatory gastrointestinal diseases was similar to normal controls but significantly less than both patients with primary operable breast cancer and patients with systemic breast cancer. Twenty patients with operable breast cancer were followed up after primary surgery by serial 3-monthly thymidine kinase levels in the disease free interval. Four patients have developed systemic recurrence with a rise in the mean thymidine kinase value to 14.3 pmol ml-1 h-1. Ten patients with advanced breast cancer had serial thymidine kinase levels measured 2-monthly during the first 6 months of primary hormone therapy. The serum values fell in all five responders (mean 9.12-4.78 pmol ml-1 h-1) and rose in all five progressors (mean 8.62-38.5 pmol ml-1 h-1). Serum thymidine kinase reflects stage of disease in breast cancer. Serial thymidine kinase levels in patients with systemic breast cancer reflected response to systemic therapy.
Similar articles
-
Thymidine kinase activities in mononuclear leukocytes and serum from breast cancer patients.Br J Cancer. 1988 Jun;57(6):619-22. doi: 10.1038/bjc.1988.141. Br J Cancer. 1988. PMID: 3408646 Free PMC article.
-
Can thymidine kinase levels in breast tumors predict disease recurrence?J Natl Cancer Inst. 1992 Dec 2;84(23):1825-8. doi: 10.1093/jnci/84.23.1825. J Natl Cancer Inst. 1992. PMID: 1433372
-
Breast tumour thymidine kinase levels and disease recurrence.Med Lab Sci. 1992 Dec;49(4):244-7. Med Lab Sci. 1992. PMID: 1339926
-
Breast and prostate cancer patients differ significantly in their serum Thymidine kinase 1 (TK1) specific activities compared with those hematological malignancies and blood donors: implications of using serum TK1 as a biomarker.BMC Cancer. 2015 Feb 18;15:66. doi: 10.1186/s12885-015-1073-8. BMC Cancer. 2015. PMID: 25881026 Free PMC article.
-
Overview of resistance to systemic therapy in patients with breast cancer.Adv Exp Med Biol. 2007;608:1-22. doi: 10.1007/978-0-387-74039-3_1. Adv Exp Med Biol. 2007. PMID: 17993229 Review.
Cited by
-
Thymidine kinase: a tumor marker with prognostic value for non-Hodgkin's lymphoma and a broad range of potential clinical applications.Ann Hematol. 1992 Jul;65(1):1-5. doi: 10.1007/BF01715117. Ann Hematol. 1992. PMID: 1643153 Review.
-
Biomedical applications of nanoflares: Targeted intracellular fluorescence probes.Nanomedicine. 2019 Apr;17:342-358. doi: 10.1016/j.nano.2019.02.006. Epub 2019 Feb 28. Nanomedicine. 2019. PMID: 30826476 Free PMC article. Review.
-
Thymidine Kinase Type 1 and C-Reactive Protein Concentrations in Dogs with Spontaneously Occurring Cancer.J Vet Intern Med. 2016 Jul;30(4):1159-66. doi: 10.1111/jvim.13954. Epub 2016 May 23. J Vet Intern Med. 2016. PMID: 27214230 Free PMC article.
-
Circulating Biomarkers of CDK4/6 Inhibitors Response in Hormone Receptor Positive and HER2 Negative Breast Cancer.Cancers (Basel). 2021 May 27;13(11):2640. doi: 10.3390/cancers13112640. Cancers (Basel). 2021. PMID: 34072070 Free PMC article. Review.
-
Serum tumour markers as a diagnostic and prognostic tool in Libyan breast cancer.Tumour Biol. 2012 Dec;33(6):2371-7. doi: 10.1007/s13277-012-0500-6. Epub 2012 Sep 5. Tumour Biol. 2012. PMID: 22948780
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical